115
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Low-dose IL-2 may enhance the effect of vedolizumab

ORCID Icon, , , ORCID Icon, &
Pages 1404-1405 | Received 07 Apr 2022, Accepted 21 May 2022, Published online: 14 Jun 2022
 

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Author contributions

CH Lee wrote the first draft of the manuscript. CH Lee, S Huang and B Nanan contributed to the initial laboratory work. P Hsu and RW Leong provide ideals and critiques regarding the study design and manuscript. R Nanan conceptualised the study.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 336.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.